Evidence map›Paper›PMID 26646002›Full record

ArticleNeurochemical research2016

Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis.

Gye Sun Jeon, Wooseok Im, Yu-Mi Shim, Mijung Lee, Myung-Jin Kim, Yoon-Ho Hong, Seung-Yong Seong, Manho Kim, Jung-Joon Sung

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Mesenchymal Stem Cells for Neurological Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Gye Sun JeonDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Wooseok ImDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Yu-Mi ShimDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Mijung LeeDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Myung-Jin KimDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Yoon-Ho HongDepartment of Neurology, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea.
Seung-Yong SeongWide River Institute of Immunology, Department of Microbiology and Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
Manho KimDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. kimmanho@snu.ac.kr.
Jung-Joon SungDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. jjsaint@snu.ac.kr.
Seoul National University Hospital · KRSeoul Metropolitan Government · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating human neurodegenerative disease. The precise pathogenic mechanisms of the disease remain uncertain, and as of yet, there is no effective cure. Human adipose stem cells (hASC) can be easily obtained during operative procedures. hASC have a clinically feasible potential to treat neurodegenerative disorders, since cytosolic extract of hASC contain a number of essential neurotrophic factors. In this study, we investigated effects of hASC extract on the SOD1 G93A mouse model of ALS and in vitro test. Administration of hASC extract improved motor function and prolonged the time until symptom onset, rotarod failure, and death in ALS mice. In the hASC extracts group, choline acetyltransferase immunostaining in the ventral horn of the lumbar spinal cord showed a large number of motor neurons, suggesting normal morphology. The neuroprotective effect of hASC extract in ALS mice was also suggested by western blot analysis of spinal cord extract from ALS mice and in vitro test. hASC extract treatment significantly increased expression of p-Akt, p-CREB, and PGC-1α in SOD1 G93A mouse model and in vitro test. Our results indicated that hASC extract reduced apoptotic cell death and recovered mutant SOD1-induced mitochondrial dysfunction. Moreover, hASC extract reduced mitochondrial membrane potential. In conclusion, we have demonstrated, for the first time, that hASC extract exert a potential therapeutic action in the SOD1 G93A mouse model of ALS and in vitro test. These findings suggest that hASC hold promise as a novel therapeutic strategy for treating ALS.

Indexed as

Adipose TissueAmyotrophic Lateral SclerosisAnimalsApoptosis Regulatory ProteinsCell ExtractsCell SurvivalCyclic AMP Response Element-Binding ProteinFemaleHumansMaleMice, TransgenicMitochondriaMotor NeuronsNeuroprotective AgentsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPhosphorylationApoptosis Regulatory ProteinsCell ExtractsCyclic AMP Response Element-Binding ProteinNeuroprotective AgentsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPpargc1a protein, mouseSuperoxide DismutaseSuperoxide Dismutase-1Transcription FactorsAmyotrophic lateral sclerosisHuman adipose stem cellsNeuroprotectionParacrine effectSOD1

Identifiers

PMID26646002
OpenAlexW2190338989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.